Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

  • Serrano Garcia, César
  • Vivancos Prellezo, Ana
  • Matito Ariza, Judit
  • Mancuso, Francesco Mattia
  • Valverde Morales, Claudia Maria
  • Quiroga Gómez, Sergi
  • Dopazo Taboada, Cristina
  • Sanso Martinez, Miriam
  • Garcia Valverde, Luis Alfonso
  • Rosell Aluja, Jordi
  • Carles Galceran, Joan
  • Arribas López, Joaquin Vicente
  • Castro Boix, Sandra
  • Landolfi, Stefania
  • Lopez Pousa, Antonio
ADN tumoral circulant; Tumor de l'estroma gastrointestinal; Imatinib, ADN tumoral circulante; Tumor del estroma gastrointestinal; Imatinib, Circulating tumor DNA; Gastrointestinal stromal tumor; Imatinib, Background Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating tumor (ct)DNA determination is expected to be an informative non-invasive dynamic biomarker in GIST patients. Methods We performed amplicon-based next-generation sequencing (NGS) across 60 clinically relevant genes in 37 plasma samples from 18 GIST patients collected prospectively. ctDNA alterations were compared with NGS of matched tumor tissue samples (obtained either simultaneously or at the time of diagnosis) and cross-validated with droplet digital PCR (ddPCR). Results We were able to identify cfDNA mutations in five out of 18 patients had detectable in at least one timepoint. Overall, NGS sensitivity for detection of cell-free (cf)DNA mutations in plasma was 28.6%, showing high concordance with ddPCR confirmation. We found that GIST had relatively low ctDNA shedding, and mutations were at low allele frequencies. ctDNA was detected only in GIST patients with advanced disease after imatinib failure, predicting tumor dynamics in serial monitoring. KIT secondary mutations were the only mechanism of resistance found across 10 imatinib-resistant GIST patients progressing to sunitinib or regorafenib. Conclusions ctDNA evaluation with amplicon-based NGS detects KIT primary and secondary mutations in metastatic GIST patients, particularly after imatinib progression. GIST exhibits low ctDNA shedding, but ctDNA monitoring, when positive, reflects tumor dynamics., This research is supported by a Fero Fellowship Award (C.S.), Asociación Española Contra el Cáncer (J.P. Barcelona) (C.S.), and ISCIII PI16/01371 (C.S.). C.S. and A.V. acknowledge to the Cellex Foundation for providing facilities and equipment. None of the funding bodies had access nor influence in the design, collection, analysis, interpretation and writing the manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Silencing of adaptor protein 32 reduces / receptors expression and impairs gastrointestinal stromal tumors growth

  • Serrano-Candelas, Eva
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Navinés-Ferrer, Arnau
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • García-Valverde, Alfonso|||0000-0002-5616-3082
  • Bazzocco, Sarah
  • Macaya, Irati|||0000-0001-5698-6452
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Serrano, Cesar|||0000-0003-1416-8739
  • Sayós, Joan|||0000-0002-4664-3461
  • Arango, Diego|||0000-0003-2953-3284
  • Martin, Margarita
Gastrointestinal stromal tumors (s) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most s contain oncogenic (85%) or (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of drug resistance has highlighted the need for novel therapeutic strategies. Recently, we reported that the adaptor molecule 3 Binding Protein 2 (32) regulates expression and signaling in human mast cells. Our current study shows that 32 is expressed in primary tumors and cell lines from patients and that 32 silencing leads to a downregulation of oncogenic and expression and an increase in apoptosis in imatinib-sensitive and imatinib-resistant cells. The microphthalmia-associated transcription factor (), involved in expression in mast cells and melanocytes, is expressed in s. Interestingly, is reduced after 32 silencing. Importantly, reconstitution of both 32 and restores cell viability. Furthermore, 32 silencing significantly reduces cell migration and tumor growth of imatinib-sensitive and imatinib-resistant cells in vivo. Altogether, 32 regulates and expression and cell viability, indicating a role as a potential target in imatinib-sensitive and imatinib-resistant s.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

  • Serrano Garcia, César
  • Vivancos Prellezo, Ana
  • Matito Ariza, Judit
  • Mancuso, Francesco Mattia
  • Valverde Morales, Claudia Maria
  • Quiroga Gómez, Sergi
  • Dopazo Taboada, Cristina
  • Sanso Martinez, Miriam
  • Garcia Valverde, Luis Alfonso
  • Rosell Aluja, Jordi
  • Carles Galceran, Joan
  • Arribas López, Joaquin Vicente
  • Castro Boix, Sandra
  • Landolfi, Stefania
  • Lopez Pousa, Antonio
ADN tumoral circulant; Tumor de l'estroma gastrointestinal; Imatinib, ADN tumoral circulante; Tumor del estroma gastrointestinal; Imatinib, Circulating tumor DNA; Gastrointestinal stromal tumor; Imatinib, Background Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating tumor (ct)DNA determination is expected to be an informative non-invasive dynamic biomarker in GIST patients. Methods We performed amplicon-based next-generation sequencing (NGS) across 60 clinically relevant genes in 37 plasma samples from 18 GIST patients collected prospectively. ctDNA alterations were compared with NGS of matched tumor tissue samples (obtained either simultaneously or at the time of diagnosis) and cross-validated with droplet digital PCR (ddPCR). Results We were able to identify cfDNA mutations in five out of 18 patients had detectable in at least one timepoint. Overall, NGS sensitivity for detection of cell-free (cf)DNA mutations in plasma was 28.6%, showing high concordance with ddPCR confirmation. We found that GIST had relatively low ctDNA shedding, and mutations were at low allele frequencies. ctDNA was detected only in GIST patients with advanced disease after imatinib failure, predicting tumor dynamics in serial monitoring. KIT secondary mutations were the only mechanism of resistance found across 10 imatinib-resistant GIST patients progressing to sunitinib or regorafenib. Conclusions ctDNA evaluation with amplicon-based NGS detects KIT primary and secondary mutations in metastatic GIST patients, particularly after imatinib progression. GIST exhibits low ctDNA shedding, but ctDNA monitoring, when positive, reflects tumor dynamics., This research is supported by a Fero Fellowship Award (C.S.), Asociación Española Contra el Cáncer (J.P. Barcelona) (C.S.), and ISCIII PI16/01371 (C.S.). C.S. and A.V. acknowledge to the Cellex Foundation for providing facilities and equipment. None of the funding bodies had access nor influence in the design, collection, analysis, interpretation and writing the manuscript.